Patents Assigned to Dharmacon, Inc.
  • siRNA targeting KRAS
    Publication number: 20090298176
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: July 6, 2009
    Publication date: December 3, 2009
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting transducin (beta)-like 3 (TBL3)
    Publication number: 20090291497
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3.
    Type: Application
    Filed: July 1, 2009
    Publication date: November 26, 2009
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
    Patent number: 7619081
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: November 17, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
    Publication number: 20090280567
    Abstract: RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5? terminal sense nucleotides with 2?-O-alkyl groups and a label on the first 5? terminal sense nucleotide, in conjunction with at least one additional 2?-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2? fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5? terminal antisense nucleotide; or (ii) a first and second 5? terminal antisense nucleotide with 2?-O-alkyl modifications and at least one additional 2?-O-alkyl pyrimidine modified antisense nucleotide.
    Type: Application
    Filed: June 17, 2009
    Publication date: November 12, 2009
    Applicant: DHARMACON, INC.
    Inventors: Devin Leake, Anastasia Khvorova, Yuriy Fedorov, Michael Owen Delaney, Barbara Robertson, Emily Anderson, Angela Reynolds
  • siRNA Targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
    Publication number: 20090281297
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MYC.
    Type: Application
    Filed: June 16, 2009
    Publication date: November 12, 2009
    Applicant: DHARMACON, INC
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting TIE-2
    Patent number: 7615541
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: November 10, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting inner centromere protein antigens (INCENP)
    Publication number: 20090275640
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.
    Type: Application
    Filed: May 12, 2009
    Publication date: November 5, 2009
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 7612196
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 3, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting ras-related nuclear protein
    Patent number: 7608706
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: October 27, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting survivin
    Patent number: 7608707
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: October 27, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting cAMP-specific phosphodiesterase 4D
    Patent number: 7605250
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: October 20, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting kinase insert domain receptor (KDR)
    Patent number: 7605252
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 20, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting gremlin
    Publication number: 20090253776
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.
    Type: Application
    Filed: May 28, 2009
    Publication date: October 8, 2009
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting histamine receptor H1
    Patent number: 7598369
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: October 6, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting polo-like kinase-1 (PLK-1)
    Patent number: 7598370
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: October 6, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting EPH receptor A3 (EPHA3)
    Patent number: 7595388
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EPHA3.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: September 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Modified polynucleotides for reducing off-target effects in RNA interference
    Patent number: 7595387
    Abstract: Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2?-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: September 29, 2009
    Assignees: Dharmacon, Inc., Merck & Co., Inc.
    Inventors: Devin Leake, Angela Reynolds, Anastasia Khvorova, William Marshall, Peter S. Linsley
  • siRNA targeting casitas B cell lymphoma-B (CBL-B)
    Patent number: 7595389
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: September 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting myeloid cell leukemia sequence 1
    Patent number: 7592444
    Abstract: Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: September 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
    Patent number: 7592442
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM 2.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: September 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe